



CPT® Category I New Immunization* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

Most recent changes to the CPT® Category I New Immunization* Vaccine Codes Long Descriptor document:

- Addition of 2 Category I codes (90616, 90639) accepted by the CPT Editorial Panel at the February 2026 meeting.

*For the purposes of CPT coding, “Immunization” includes vaccines/toxoids, immune globulins, serum or recombinant products.

It is important to note that further CPT Editorial Panel or Executive Committee actions may affect these codes and/or descriptors. For this reason, code numbers and/or descriptor language in the CPT code set may differ at the time of publication. In addition, further Panel actions” may result in gaps in code number sequencing.

The removal of the FDA pending symbol follows notification that this product has been granted FDA approval status on the date indicated. Code 90624 was originally published in CPT 2025.

***Note that code 90624 will follow code 90623.**

Codes	Long Descriptor	Released to AMA Website	FDA Approval Effective	Publication
# ● 90624	Meningococcal pentavalent vaccine, Men B-4C recombinant proteins and outer membrane vesicle and conjugated Men A, C, W, Y-diphtheria toxoid carrier, for intramuscular use	February 2, 2026	November 21, 2024	CPT® 2027

The following immunization codes were accepted at the February 2026 CPT Editorial Panel meeting for the 2027 CPT production cycle. These codes are effective on July 1, 2026 following the three-month implementation period which begins April 1, 2026.

***Note that code 90616 will follow code 90673, and code 90639 will follow code 90637.**

# ● 90616	Influenza virus vaccine, trivalent (tIRV), mRNA, 37.5 mcg/0.38 mL dosage, for intramuscular use	April 1, 2026	July 1, 2026	CPT® 2027
# ● 90639	Influenza virus vaccine, quadrivalent (qIRV), mRNA; 50 mcg/0.5 mL dosage, for intramuscular use	April 1, 2026	July 1, 2026	CPT® 2027